Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01018095 · ClinicalTrials.gov registry record · Phase 4
Trichomonas Vaginalis Recurrence Among HIV+ Women
A Phase 4 study, sponsored by Tulane University Health Sciences Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 270
- Enrollment target
NCT01018095 is a Phase 4 study that has completed, run by Tulane University Health Sciences Center. The registered enrollment target is 270 participants.
The verdict
NCT01018095, a Phase 4 study, has completed, sponsored by Tulane University Health Sciences Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 270 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the 2 gram single dose of metronidazole is as effective as the 7 day 500 mg BID dose for treatment of Trichomonas vaginalis (TV) among HIV-infected women.
Interventions
- DRUG Metronidazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2005-05 |
| Est. Completion | 2009-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01018095
The ClinicalTrials.gov registry entry for NCT01018095 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 270 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tulane University Health Sciences Center, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Metronidazole is the first listed.
NCT01018095 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01018095 about?
NCT01018095 is a clinical study titled "Trichomonas Vaginalis Recurrence Among HIV+ Women". The purpose of this study is to determine if the 2 gram single dose of metronidazole is as effective as the 7 day 500 mg BID dose for treatment of Trichomonas vaginalis (TV) among HIV-infected women.
What is the current status of trial NCT01018095?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 270 participants. The study started on 2005-05. Estimated completion is 2009-08.
What interventions are being tested in trial NCT01018095?
The interventions under investigation include: Metronidazole (DRUG).
Who is sponsoring clinical trial NCT01018095?
This trial is sponsored by Tulane University Health Sciences Center, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.